EBOV NP Specific Neutra™ Antibody Products

Are you facing difficulties with the highly pathogenicity of the Ebola virus, obstacles in creating reliable diagnostic tests, or the pressing demand for effective therapeutic options? Creative Biolabs' EBOV NP Specific Neutra™ Antibody Products empower your research with high-affinity, rigorously validated neutralizing antibodies, engineered through advanced hybridoma and phage display platforms, to accelerate your therapeutic discovery and diagnostic development against Ebola Virus Disease.

Introduction to Ebola Virus Nucleoprotein (EBOV NP)

The Ebola virus nucleoprotein (EBOV NP) is a critical structural and functional component essential for viral replication and pathogenesis. As the most abundant protein in the infected cell, it plays a central role in encapsidating the viral genomic RNA, forming the ribonucleoprotein complex (RNP), and orchestrating viral transcription and replication. EBOV NP is a multi-functional, RNA-binding protein expressed abundantly during infection. It exhibits high immunogenicity, making it a prime target for both diagnostic detection and host immune response.

• Structural Insights

Structurally, EBOV NP consists of N- and C-terminal domains connected by a flexible linker. The N-terminal domain is responsible for RNA binding and oligomerization, forming a helical lattice that protects the viral genome. The C-terminal domain is involved in NP-NP interactions and recruitment of the viral polymerase cofactor, VP30. This intricate architecture is vital for the formation of the replication-competent RNP core.

Fig.1 Ebola virus architecture and its genomic composition.¹

• Resistance and Signaling Pathways

EBOV NP actively subverts host antiviral defenses. It has been shown to inhibit the host interferon (IFN) response by blocking IFN signaling pathways, including the JAK-STAT cascade. Furthermore, NP interacts with cellular proteins involved in stress granule formation, disrupting this innate immune mechanism to facilitate viral replication.

• Clinical Impact

Ebola Virus Disease is a severe, often fatal hemorrhagic fever. EBOV NP is a key driver of pathogenesis, contributing to massive viral replication, immune evasion, and the cytokine storm characteristic of severe EVD.

• Antibodies Against EBOV NP

Neutralizing antibodies targeting EBOV NP offer unique advantages. Unlike antibodies against the glycoprotein GP, which must contend with immune evasion mechanisms like mucin-like domain shielding, anti-NP antibodies can target highly conserved epitopes. They are crucial for:

Precise Detection: Enabling highly sensitive and specific diagnostic assays for early EVD detection.

Mechanistic Studies: Unraveling the intricate details of viral replication, RNP assembly, and host-virus interactions.

Therapeutic Potential: Disrupting essential NP functions, such as oligomerization or RNA binding, to inhibit viral replication, offering a complementary strategy to GP-targeted therapies.

Applications of Anti-EBOV NP Neutralizing Antibodies

Fig.2 Identification of NXF1 domains critical for NP interaction through SDS-PAGE and Western blot analyses of anti-NP antibodies.²

• High-Sensitivity Diagnostic Assay Development

Anti-EBOV NP antibodies are the cornerstone of modern EVD diagnostics. Their high affinity for the abundant NP antigen enables the development of rapid diagnostic tests (RDTs), ELISA, and Luminex-based assays with exceptional sensitivity and specificity for early infection. These tools are vital for outbreak containment, patient triage, and surveillance, providing results in minutes to hours compared to days for PCR in resource-limited settings.

• Therapeutic Intervention and Mechanism Elucidation

While traditionally seen as diagnostic tools, high-potency neutralizing anti-NP antibodies represent a promising therapeutic avenue. By binding to critical functional domains, they can disrupt RNP assembly, inhibit viral RNA synthesis, and block essential protein-protein interactions within the viral replication machinery. This mechanism offers a potent means to halt viral propagation, potentially in synergy with GP-targeting antibodies.

• Vaccine Efficacy and Immune Response Monitoring

Quantifying anti-NP antibody titers is a robust correlate of protective immunity in vaccine studies. NP is a major target of the cellular and humoral immune response. Assays utilizing our Neutra™ anti-NP antibodies allow researchers to accurately measure immunogenicity, track longitudinal immune responses in vaccinated individuals, and assess the protective efficacy of candidate vaccines in preclinical and clinical trials.

Our Anti-EBOV NP Neutralizing Antibodies

Creative Biolabs delivers premium antibody reagents designed to meet the stringent demands of filovirus research:

• High Specificity and Affinity: Rigorously validated for minimal cross-reactivity, ensuring accurate detection and functional neutralization of EBOV NP.
• Robust Validation: Performance-guaranteed across key stringent quality controls to ensure batch-to-batch reliability for your critical projects.

With over two decades of expertise in virology and antibody engineering, Creative Biolabs is your trusted partner in combating high-threat pathogens. We combine deep scientific knowledge with cutting-edge platform technology to provide researchers with powerful, reliable tools that accelerate timelines from discovery to development. Our EBOV GP Specific Neutra™ Antibody Products embody this commitment, offering the quality and validation necessary to advance your therapeutic, vaccine, and diagnostic programs. Reach out to our team today to gain further insights and discuss the specific requirements of your project.

References

1. Singh, Raj Kumar, et al. "Ebola virus–epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans–an update on its 40 year's journey." Veterinary Quarterly 37.1 (2017): 98-135. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1038/s42003-022-03767-1
2. Wendt, Lisa, et al. "The Ebola virus nucleoprotein recruits the nuclear RNA export factor NXF1 into inclusion bodies to facilitate viral protein expression." Cells 9.1 (2020): 187. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.3390/cells9010187